Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ultragenyx Pharmaceu (NQ: RARE ) 53.05 +1.32 (+2.55%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 16, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Ultragenyx Pharmaceu < Previous 1 2 3 4 5 Next > Novartis And Viatris Sued Over Unlawful Use Of HeLa Cells Used For Cancer Treatment Drugs August 06, 2024 Henrietta Lacks' family sues Novartis and Viatris for profiting from her HeLa cells without consent. The lawsuit seeks profits and aims to prevent further unauthorized use of the cells. Via Benzinga Topics Lawsuit Exposures Financial Legal 3 Genomics Stocks That May Transform Personalized Medicine August 06, 2024 These are three of the best genomics stocks to buy for a lucrative entry into a specialized section of the biotech industry. Via InvestorPlace Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst July 22, 2024 Ionis Pharmaceuticals releases positive results from Phase 1/2 study of ION582 for Angelman syndrome, showing consistent clinical improvements in communication, cognition, and motor function. Safety... Via Benzinga Unveiling 14 Analyst Insights On Ultragenyx Pharmaceutical July 22, 2024 Via Benzinga Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong July 22, 2024 Biogen previously decided against opting into Ionis' Angelman program. Via Investor's Business Daily Peeling Back The Layers: Exploring Ultragenyx Pharmaceutical Through Analyst Insights May 31, 2024 Via Benzinga Forecasting The Future: 11 Analyst Projections For Ultragenyx Pharmaceutical April 22, 2024 Via Benzinga Expert Outlook: Ultragenyx Pharmaceutical Through The Eyes Of 9 Analysts April 05, 2024 Via Benzinga 7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline June 17, 2024 With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities. Via InvestorPlace Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session June 14, 2024 Via Benzinga Dave & Buster's Posts Downbeat Results, Joins J.Jill And Other Big Stocks Moving Lower In Thursday's Pre-Market Session June 13, 2024 Via Benzinga Analyst Scoreboard: 8 Ratings For Ultragenyx Pharmaceutical March 18, 2024 Via Benzinga Recap: Ultragenyx Pharmaceutical Q4 Earnings February 15, 2024 Via Benzinga The Latest Analyst Ratings For Ultragenyx Pharmaceutical February 15, 2024 Via Benzinga This United Airlines Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday June 06, 2024 Via Benzinga Ultragenyx Faces Lawsuit Over Alleged Unjust Use of Henrietta Lacks' Cells May 22, 2024 The estate of Henrietta Lacks can proceed with a lawsuit against Ultragenyx Pharmaceutical over the use of HeLa cells taken without her consent in the 1950s. A Maryland federal court ruled against... Via Benzinga Topics Lawsuit Exposures Financial Legal RARE Stock Earnings: Ultragenyx Pharmaceutical Misses EPS, Misses Revenue for Q1 2024 May 02, 2024 RARE stock results show that Ultragenyx Pharmaceutical missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. Via InvestorPlace S&P 500 Down Over 1%; US Retail Sales Increase 0.7% In March April 15, 2024 U.S. stocks turned lower toward the end of trading, with the S&P 500 falling more than 1% on Monday. The Dow traded down 0.64% to 37,741.18 while the NASDAQ fell 1.68% to 15,902.96. The S&P 500 also... Via Benzinga Topics Stocks Exposures US Equities Crude Oil Down 1%; Charles Schwab Sales Top Estimates April 15, 2024 U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 100 points on Monday. The Dow traded up 0.35% to 38,114.61 while the NASDAQ rose 0.07% to 16,187.02. The S&P... Via Benzinga Topics Stocks Exposures Fossil Fuels US Equities Earnings Scheduled For February 15, 2024 February 15, 2024 Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. Via Benzinga Preview: Ultragenyx Pharmaceutical's Earnings February 14, 2024 Via Benzinga 4 Analysts Have This To Say About Ultragenyx Pharmaceutical January 19, 2024 Via Benzinga Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session April 15, 2024 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic... Via Benzinga Rare Disease-Focused-Ultragenyx Pharmaceutical Stock Falls On Serious Adverse Events In Eaarly Genetic Disorder Study April 15, 2024 New data from Phase 1/2 study of GTX-102 for Angelman syndrome shows rapid and sustained improvement in patients, exceeding natural history data. Via Benzinga Marinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session April 15, 2024 U.S. stock futures were higher this morning, with the Dow futures gaining over 200 points on Monday. Via Benzinga Topics Stocks Exposures US Equities Expert Ratings for Ultragenyx Pharmaceutical December 08, 2023 Via Benzinga Analyst Ratings for Ultragenyx Pharmaceutical November 03, 2023 Via Benzinga Ultragenyx Pharm Stock Earns IBD Stock Upgrade With RS Rating Jump To 83 January 18, 2024 On Thursday, Ultragenyx Pharm stock just cleared that 80 or higher RS Rating benchmark with an upgrade from 75 to 83. Via Investor's Business Daily Ultragenyx Pharm Stock Hits 80-Plus Relative Strength Rating Benchmark December 28, 2023 On Thursday, Ultragenyx Pharm stock received a positive adjustment to its Relative Strength (RS) Rating, from 77 to 81. Via Investor's Business Daily Earnings Outlook For Ultragenyx Pharmaceutical November 01, 2023 Via Benzinga < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.